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Abstract
Background: Mitochondria are considered a primary intracellular site of reactive oxygen species (ROS) generation.
Generally, cancer cells with mitochondrial genetic abnormalities (copy number change and mutations) have
escalated ROS levels compared to normal cells. Since high levels of ROS can trigger apoptosis, treating cancer cells
with low doses of mitochondria-targeting / ROS-stimulating agents may offer cancer-specific therapy. This study
aimed to investigate how baseline ROS levels might influence cancer cells’ response to ROS-stimulating therapy.
Methods: Four cancer and one normal cell lines were treated with a conventional drug (cisplatin) and a
mitochondria-targeting agent (dequalinium chloride hydrate) separately and jointly. Cell viability was assessed and
drug combination synergisms were indicated by the combination index (CI). Mitochondrial DNA copy number
(mtDNAcn), ROS and mitochondrial membrane potential (MMP) were measured, and the relative expression levels
of the genes and proteins involved in ROS-mediated apoptosis pathways were also investigated.
Results: Our data showed a correlation between the baseline ROS level, mtDNAcn and drug sensitivity in the
tested cells. Synergistic effect of both drugs was also observed with ROS being the key contributor in cell death.
Conclusions: Our findings suggest that mitochondria-targeting therapy could be more effective compared to
conventional treatments. In addition, cancer cells with low levels of ROS may be more sensitive to the treatment,
while cells with high levels of ROS may be more resistant. Doubtlessly, further studies employing a wider range of
cell lines and in vivo experiments are needed to validate our results. However, this study provides an insight into
understanding the influence of intracellular ROS on drug sensitivity, and may lead to the development of new
therapeutic strategies to improve efficacy of anticancer therapy.
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Background
Mitochondria are implicated in many cellular processes
such as cellular energy metabolism, cell communication,
differentiation and apoptosis [1]. Mitochondrial dysfunc-
tion leads to alterations in mitochondrial structure, dis-
ruption of mitochondrial membrane potential, instability
of electron transport reactions resulting in reactive oxy-
gen species (ROS) overproduction, activation of caspase
cascades and initiation of apoptosis pathway. Hence, any
mitochondrial abnormality can lead to the development
of several human diseases, including cancers [2]. One
unique feature of mitochondria is that they contain their
own genome, mitochondrial DNA (mtDNA; a small
circular DNA of approximately 16,569 bp), independent
of nuclear DNA [3].
Mitochondria are the primary source of intracellular
ROS, a group of chemically reactive molecules containing
oxygen, hydroxyl radical (•OH), superoxide anion (O2
−),
singlet oxygen (O2) and hydrogen peroxide (H2O2), as
side-products of the mitochondrial electron transport
chain reaction during cellular respiration [4]. ROS play
important roles in cell signalling pathways such as growth,
differentiation, metabolism and apoptosis [4, 5]. They are
also regarded as a double-edged sword in cancer cells
since low doses of ROS can promote cell proliferation and
invasion, whereas excessive levels of ROS cause oxidative
damage to proteins, lipids, RNA and DNA which conse-
quently induce cell death [6, 7]. Therefore, a slight in-
crease of ROS is associated with the initiation and
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progression of cancer [4, 8], but high levels of ROS can in-
duce cell death by activating several signalling pathways
resulting in cell apoptosis [6, 7]. For example, in cancer
cells with wild type p53, DNA damage by ROS induces
apoptosis in a mitochondria-dependent manner via activa-
tion of the p53/BAX signalling pathway [4]. In healthy tis-
sues, the intracellular ROS are preserved at a steady and
low level by the equilibrium between ROS production and
elimination by enzymatic antioxidants such as cytoplasmic
superoxide (SOD1), mitochondrial superoxide (SOD2),
catalase (CAT) and glutathione (GSH) [9]. Tumour cells
express lower antioxidants than normal cells, and there-
fore have higher ROS levels. Furthermore, defective mito-
chondrial oxidative metabolism in tumour cells also
render higher ROS levels [9], and therefore ROS induction
is a promising approach to cancer therapy [4, 8].
Despite its strong side effects, chemotherapy is still
widely used in clinical practice. Many chemotherapy
drugs cause cell death by a direct damage to the nucleic
acids while others disrupt the redox balance within the
cell. Some chemotherapeutic agents can cause an ex-
cessive accumulation of ROS either via an overproduc-
tion of ROS or by supressing their elimination in
tumour cells by the antioxidant systems [10]. Cisplatin
[cisplatinum or cis-diamminedichloroplatinum (II)] is
one of the most commonly used chemotherapeutic
agents employed in the treatment of various human
cancers. It is a highly reactive molecule which forms
various types of adducts by binding to DNA, RNA and
proteins, and the cytotoxic effect of cisplatin is mainly
due to the lesions formed within the nuclear DNA [11].
Moreover, previous studies have demonstrated that cis-
platin accumulates in mitochondria and causes signifi-
cant changes in mitochondrial structure and metabolic
function [11, 12]. Recent reports evinced that cisplatin-
induced apoptosis could be inhibited by compounds
that interfere with ROS generation. These observations
elucidate that the killing effect is correlated to in-
creased ROS generation [12]. However, the clinical use
of cisplatin is limited because of its severe irreversible
side effects including neurotoxicity, ototoxicity and
nephrotoxicity which has been reported as the main
limitation of cisplatin [13]. Furthermore, the majority
of current systemic cancer chemotherapeutic drugs
exert their toxicity on mitochondria indirectly via dif-
ferent signalling pathways, and they do not localise at
tumour sites efficiently and therefore can cause un-
wanted damage to normal tissues [2, 14].
Recently, due to their critical role in metabolism, ATP
synthesis and redox status, and because of their involve-
ments in many pathways related to the cell death, mito-
chondria have become one of the main interests in
developing cancer treatments. Since cancer cells gener-
ally have higher levels of ROS compared to normal cells,
and because of the differences in the mitochondrial
membrane potential between cancer and normal cells, a
direct targeting on mitochondrial functions could be an
effective approach to triggering cancer-specific cell
death. Delocalised lipophilic cations (DLCs), a group of
small membrane permeable agents driven by negative
potential across the mitochondrial membrane, accumu-
late in mitochondria and are more toxic to cancer cells
compared to normal cells [15]. This characteristic at-
tracts researchers to evaluate DLCs for selective cancer
cell elimination [16]. Within a wide range of DLCs,
dequalinium (DQA) has been reported to demonstrate a
potent anticancer activity in vitro and in vivo in different
malignancies [14]. Several studies have suggested that
the cytotoxicity mechanism of DQA is related to mito-
chondrial dysfunction due to the damage of mitochon-
drial DNA and the inhibition of mitochondrial complex
I [17]. It has also been reported that DQA causes cell
death in the HeLa cells by selective depletion of mtDNA
[18]. Moreover, it has been postulated that DQA induces
human leukaemia cell death by affecting the redox bal-
ance [19], and another study showed that DQA caused
oxidative stress and apoptosis in a human prostate can-
cer cell line [20].
Due to the merit of mitochondria-targeting therapy,
the combination of conventional chemotherapy drugs
such as cisplatin with mitochondria-targeting agents
may offer a promising strategy for enhanced anticancer
therapy [21]. Furthermore, mitochondrial DNA copy
number (mtDNAcn) per cell is preserved within a stable
range to achieve the required energy of the cell and
hence ensure normal physiological functions. It ranges
from 103 to 104 according to the population and cell
type. Such variations also reflect the imbalance between
ROS production and the antioxidant capacity, so
mtDNAcn has been considered as a potential diagnostic
and prognostic biomarkers for several cancer types [22].
This study aimed to investigate the link between
mtDNAcn and baseline intracellular ROS level in untreated
cancer cells, as well as how baseline ROS level might influ-
ence cells’ response to ROS-stimulating therapy. The po-
tential synergistic effect of cisplatin and dequalinium
chloride in killing cancer cells was also assessed.
Methods
Cell culture
The four cancerous (Ishikawa/endometrium, MDA-MB-
231/breast, Caco-2/colon, PC-3/prostate) and one normal
(PNT-2/prostate) cell lines were obtained from the de-
partmental cell bank at the University of Portsmouth. All
cell lines were originally purchased from the European
Collection of Authenticated Cell Cultures/ECACC (Ishi-
kawa, MDA-MB-231, Caco-2, PNT-2) or the American
Type Culture Collection/ATCC (PC-3). Ishikawa (Cat.
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99040201), Caco-2 (Cat. 86010202) and PNT-2 (Cat.
95012613) were purchased in 2015; MDA-MB-231 (Cat.
92020424) and PC-3 (Cat. CRL-1435) were purchased in
2013. Cells were maintained in required media (Add-
itional file 1: Table S1) and harvested at 90% confluence
for the downstream assays. All cell lines were authenticated
to confirm their identities by STR (short tandem repeat)
DNA profiling using the PowerPlex 16 HS System (Pro-
mega, Southampton, UK) and screened for mycoplasma
contamination using the PCR Mycoplasma Test Kit (Pro-
moCell, Heidelberg, Germany). Cell authentication and
mycoplasma detection tests were conducted in the begin-
ning, the middle and towards the end of the investigation
according to the established protocols in our laboratories.
Drug treatment
Stock solutions of cisplatin (CDDP) and dequalinium
chloride hydrate (DQA) (Sigma, Dorset, UK) were pre-
pared at 100 mM in DMSO and 2mM in distilled water,
respectively. Both drugs were added to the cells in vari-
ous concentrations and incubated for 24 h to determine
their IC50s (IC50: the half maximal inhibitory concen-
tration) which were used in all subsequent experiments.
N-Acetyl-L-cysteine (NAC) (Sigma), a powerful antioxi-
dant, was dissolved in distilled water at the concentra-
tion of 100 mM shortly before each experiment, and the
pH was adjusted to 7.4 before diluting the solution to
the working concentration (10 mM) with complete cell
culture medium. Cells were pre-incubated with NAC
(10mM) for 1 h prior to the CDDP and DQA treat-
ments. All experiments related to NAC followed the
same procedure as described in the sections below.
Cell viability assay
Cell viability was measured colorimetrically using 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) (CellTiter 96 Aque-
ous) (Promega). Briefly, 90 μl of cell suspension contain-
ing 10,000 cells was added in each well of the 96-well
plate and incubated for 24 h. Cells were then treated
with the 10 × drug solution (10 μl) for the desired
amount of time. At the end of the experiment, the
medium was replaced with 100 μl of fresh medium con-
taining MTS (final concentration - 0.3 mg/ml) and incu-
bated for 90–180 min according to the optimised
protocol for each cell line. Absorbance was measured
using the microplate reader (Multiskan® GO) at 490 nm.
IC50 was calculated as the concentration of the drug
that caused a 50% loss of metabolic activity.
Combination index (CI) for synergism assessment
The synergistic effect of CDDP and DQA was assessed
by the CI values calculated at different drug combina-
tions according to the median-effect principle of the
Chou and Talalay method, using the CompuSyn Soft-
ware 1.4 [23]. The CI values indicate how drug combina-
tions influence the therapeutic efficacy, i.e. CI > 1 –
Antagonistic; CI = 1 – Additive; CI < 1 – Synergistic.
ROS assays
Baseline intracellular ROS levels were measured in a 96-
well plate format using the Cellular Reactive Oxygen Spe-
cies Detection Assay Kit (Abcam, Cambridge, UK) based
on a fluorogenic dye, H2DCFDA, according the manufac-
turer’s protocol. Cells (25,000/well) were seeded in the 96-
well black-wall plate (Corning, NY, USA) overnight prior to
the experiments. In the following day, cells were washed
with HBSS (150 μl; Gibco, ThermoFisher Scientific, Lough-
borough, UK), then staining buffer (100 μl, 20 μM of
H2DCFDA in HBSS) was added to each well, and the plate
was incubated for 40min at 37 °C. The cells were then
washed with HBSS, and HBSS (100 μl) was added to each
well. Fluorescence was measured using the microplate
reader (POLARstar Omega) at 485 nm (excitation) and 535
nm (emission). For determining intracellular ROS levels
upon treatments, the staining buffer was added and then
the plate was incubated with the treatment solution for the
desired amount of time before fluorescence was measured.
To measure mitochondrial superoxide, the same proced-
ure was conducted as described above using a mitochon-
drial ROS specific dye, MitoSOX™ (Life Technologies,
ThermoFisher Scientific), instead of H2DCFDA. The cells
were incubated with 5 μM of MitoSOX in HBSS. Fluores-
cence was measured using the same microplate reader at
510 nm (excitation) and 580 nm (emission).
Mitochondrial membrane potential assay
MMP was measured by staining the cells with the JC-10
fluorescent dye (Enzo Life Sciences, Exeter, UK) accord-
ing the manufacturer’s protocol. Briefly, 25,000 cells
were seeded in each well of the 96-well black-wall plate
overnight prior to the experiments. The next day, cells
were treated with required concentrations of the drugs
for the desired amount of time. Following drug treat-
ments, cells were washed with HBSS, then staining buf-
fer (100 μl, 20 μM of JC-10 in HBSS) was added to each
well and the plate was incubated for 40 min at 37 °C.
Cells were then washed again with HBSS and HBSS
(100 μl) was added to each well before reading the plate.
Red and green fluorescence were measured using the
microplate reader (POLARstar Omega) at 540 nm (exci-
tation) / 590 nm (emission) and 490 nm (excitation) /
525 nm (emission), respectively.
DNA extraction and measurement of mtDNAcn by SYBR
Green real-time PCR
Total DNA was isolated from untreated and treated (24-
h incubation) cells using the QIAmp DNA Mini Kit
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(QIAGEN, Hilden, Germany) according to the manufac-
ture’s protocol. Relative quantification of mtDNAcn was
measured using the QuantiTect SYBR Green PCR kit
(QIAGEN) and run on a LightCycler® 96 System (Roche,
Basel, Switzerland) according to previously published
method [24]. The relative quantity of mtDNA content in
each sample was calculated by normalising the copy
number of mtDNA against that of the housekeeping
gene, β-actin. Three independent experiments were car-
ried out and all samples were run in triplicates in each
experiment.
RNA extraction, reverse transcription and TaqMan real-
time PCR
Total RNA was isolated from untreated and treated (24-h
incubation) cells using the RNeasy Mini Kit (QIAGEN)
according to the manufacturer’s protocol. In the last step,
RNA was eluted with RNA–free sterile water (40 μl).
cDNA was synthesised using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, California,
USA) with 1 μg of RNA template in a 20-μl reaction.
TaqMan real-time PCR was performed using the pre-
designed assays (Integrated DNA Technologies, Belgium)
to measure expression levels of antioxidant genes includ-
ing SOD1, SOD2 and CAT (Additional file 1: Table S2).
The experiments were performed using the FastStart Es-
sential DNA Probes Master (Roche) and run on a Light-
Cycler® 96 System (Roche). The amplification procedure
entailed 45 cycles of 95 °C for 10 s followed by 60 °C for
30 s. For each reaction, GAPDH was utilised as the en-
dogenous control gene. The average mRNA fold change
in drug-treated samples was normalised against untreated
samples using the 2-ΔΔCT method. Three independent ex-
periments were carried out and all samples were run in
triplicates in each experiment.
Western blotting
WB was performed to measure the BCL-XL and released
cytochrome c proteins from mitochondria according to
the established protocols in our laboratories. Briefly, pro-
tein extracts (20 μg) were resolved by SDS-PAGE electro-
phoresis, and the blots were visualised using a high-
sensitivity CCD camera imaging platform (Chemidoc MP;
Bio-Rad, Watford, UK). ImageJ software was used for the
densitometric quantification of the western blot bands.
The primary and secondary antibodies employed in the
experiments are listed in Additional file 1: Table S3.
Caspase activity assay
Caspase-3/7 activity was measured using the Caspase-
Glo 3/7 reagent from the ApoTox-Glo™ Triplex Assay
kit (Promega). According to the manufacture protocol,
90 μl of cell suspension containing 20,000 cells was
added in each well of the 96-well black-wall plate and
incubated overnight. Cells were then treated with drugs
for 24 h. At the end of the experiment, fresh Caspase-
Glo 3/7 reagent (100 μl) was added to each well, and the
plate was incubated for 60 min at room temperature. Lu-
minescence was then measured using the microplate
reader (POLARstar Omega).
Statistical analyses
Data were analysed with the GraphPad Prism 8.0 pro-
gram (Graphpad software, CA, USA) and presented as
the mean ± SEM of at least three separate experiments.
Specific statistical tests used to analyse various data sets
are described in the associated figure legends. Differ-
ences between groups were considered statistically sig-
nificant according the following criteria: *p < 0.05, **p <
0.01, ***p < 0.001 and ****p < 0.0001.
Results
Correlation between baseline ROS level, mtDNAcn and
drug sensitivity in cancer cells
The H2DCFDA and MitoSOX assays results indicated
that the Caco-2 cell line had the highest baseline ROS
and mitochondrial superoxide levels whereas Ishikawa
had the lowest (p < 0.0001; Fig. 1a & b). The baseline
ROS level correlated positively to the mtDNA copy
number amongst the cell lines, as shown in Fig. 1c that
the Caco-2 cell line had the highest mtDNA copy num-
ber whereas Ishikawa the lowest (p < 0.0001). To evalu-
ate the drug sensitivity of all the cell lines towards
CDDP and DQA, cells were treated with various concen-
trations of the drugs separately for 24 h. The results
showed that the Ishikawa cells were significantly more
sensitive to both drugs compared to other cell lines
whereas the Caco-2 cells were significantly more resist-
ant (Fig. 1d & e). The IC50s of the cell lines were calcu-
lated, and the results showed that the IC50s of CDDP
were 84.96 ± 3, 158.9 ± 8.2, 372.7 ± 17.5 and 499.5 ±
15.1 μM for Ishikawa, MDA-MB-231, PC-3 and Caco-2,
respectively, whereas the IC50s of DQA were 14.24 ±
0.59, 57.85 ± 3.59, 93.31 ± 3.21 and 179.2 ± 5.2 μM for
the above cell lines. Based on these observations, the
Caco-2 and Ishikawa cell lines were chosen to represent
the most resistant and sensitive cell lines respectively in
the downstream experiments to investigate the under-
lying killing mechanisms that might be influenced by
baseline intracellular ROS levels.
Synergistic effect of CDDP and DQA observed in Ishikawa
and Caco-2
Incubation with a combined treatment of CDDP and
DQA at half of their IC50 concentrations resulted in a
marked reduction of cell viability in both Caco-2 and
Ishikawa cells, compared to the cells treated with a sin-
gle drug (either CDDP or DQA) at its IC50 (Fig. 2a &
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b). Moreover, treating cells with various concentrations
of CDDP in combination with DQA at half of its IC50
(i.e. 89.6 μM for Caco-2 and 7.2 μM for Ishikawa) re-
sulted in a significant decrease of CDDP IC50 for the
Caco-2 (384 ± 8.3 μM) (p < 0.01) and Ishikawa
(21.8 ± .91 μM) (p < 0.0001) cells (Fig. 2c & d). Data
from the CompuSyn analysis also indicated synergistic
effects of the compounds within the concentration range
of 5–250 μM and 5–1000 μM for CDDP in Caco-2 and
Ishikawa, respectively (Additional file 1: Table S4).
Intracellular ROS and mitochondrial superoxide levels
increased upon treatments
Continuous exposure to CDDP and DQA at their IC50
concentrations and to the combination of both drugs at
half of their IC50 concentrations for 24 h resulted in
significant increases of general intracellular and mito-
chondrial ROS levels in both Caco-2 and Ishikawa cells
in a time-dependent manner. Significant increases in
intracellular ROS were observed in the Caco-2 cells at
5 h following initial exposures to CDDP and the
combined therapy (p < 0.01) (Additional file 1: Figure
S1a & c), and at 7 h following DQA treatment
(p < 0.001) (Additional file 1: Figure S1b). ROS levels
increased continuously up to 24 h in the Caco-2 cells
under all treatments. Earlier increases of intracellular
ROS were observed in the Ishikawa cells, i.e. at 3 h fol-
lowing initial exposures to CDDP and DQA (p < 0.001)
(Additional file 1: Figure S1d & e), and at 1 h with the
combined therapy (p < 0.05) (Additional file 1: Figure
S1f). Parallel increases in mitochondrial superoxide
were observed in both cell lines (Additional file 1: Fig-
ure S1). Furthermore, greater increases in intracellular
ROS and mitochondrial superoxide were observed with
the combined therapy compared to single treatment of
CDDP or DQA in the Caco-2 cells at 24 h (p < 0.0001;
Fig. 3a & b). On the contrary, ROS production was
equally elevated in the Ishikawa cells under all treat-
ment conditions (Fig. 3c & d). However, the Ishikawa
cells showed markedly higher increases in intracellular
ROS and mitochondrial superoxide upon treatments
compared to Caco-2 (Fig. 3e & f).
Fig. 1 Correlation between the baseline ROS level, mtDNA copy number and drug sensitivity. Intracellular ROS (a) and mitochondrial superoxide
(b) levels of the Ishikawa, MDA-MB-231, PC-3 and Caco-2 cell lines are represented by the fluorescence intensity of H2DCFDA and MitoSOX
respectively. (c) Relative content of mtDNA in Ishikawa, MDA-MB-231, PC-3 and Caco-2 normalised against the house keeping gene (β-actin). The
columns represent the relative mtDNA copy numbers of the cell lines. Comparison of the CDDP IC50s (d) and the DQA IC50s (e) amongst the 4
cell lines. The columns represent the CDDP IC50s and the DQA IC50s in the cell lines. Data are mean ± SEM (N = 3 separate experiments) in all of
the figure panels; p values were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; *p < 0.05, **p < 0.01,
***p < 0.001 and ****p < 0.0001
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Cell viability and mitochondrial membrane potential
reduction along the same timeline as increased ROS
generation
A decrease in cell viability was observed following the
treatments in both cell lines in a time-dependent man-
ner (Additional file 1: Figure S2), and this change corre-
lated with a decrease in MMP (Additional file 1: Figure
S3). Our data showed that CDDP noticeably depolarised
mitochondrial potential at 1 and 3 h in Ishikawa and
Caco-2, respectively, and MMP continued to reduce up
to 24 h in both cell lines. Interestingly, cells treated with
DQA and the combined therapy showed significantly
greater mitochondrial depolarisation at the 1-h time
point compared to the CDDP treatment in both cell
lines, predominantly in Ishikawa. As described above,
ROS generation (Additional file 1: Figure S1) was also
time-dependent within the 24-h drug treatment period.
MtDNAcn decreased upon treatments
Incubation with CDDP, DQA and their combination for
24 h resulted in a marked reduction of mtDNAcn in
both cell lines (Additional file 1: Figure S4), with the
copy number at its lowest value in Caco-2 undergone
the combined treatment (p < 0.0001; Additional file 1:
Figure S4a).
Cancer-preferential uptake of DQA
The JC-10 assay results indicated that the PC-3 cells
(prostate cancer) had much higher MMP compared to
their non-cancerous counterparts, the PNT-2 cells
(Additional file 1: Figure S5a). Exposing to 10 μM of
DQA resulted in a more rapid mitochondrial depolar-
isation in PC-3 compared to PNT-2 during a 3-h incu-
bation (Additional file 1: Figure S5b).
Fig. 2 Comparison of Caco-2 (a) and Ishikawa (b) cell viability upon treatments with CDDP and DQA at their IC50 concentrations, and a
combination of ½ IC50 of both drugs at 24 h. The columns represent cell viability under various treatment conditions normalised against the
untreated controls. Data are mean ± SEM (N = 3 separate experiments); p values comparing single and combined treatments were calculated
using one-way ANOVA with Tukey multiple comparison post-hoc analysis; *p < 0.05, **p < 0.01. c Comparison between the CDDP IC50 (499.5 μM)
in single drug treatment and the new CDDP IC50 (384 μM) in combination with ½ DQA IC50 in the Caco-2 cells. d Comparison between the
CDDP IC50 (84.9 μM) in single drug treatment and the new CDDP IC50 (21.8 μM) in combination with ½ DQA IC50 in the Ishikawa cells. Data are
mean ± SEM (N = 3 separate experiments); p values comparing single and combined treatments were calculated using a two-tailed t-test;
**p < 0.01 and ****p < 0.0001
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ROS as the main contributor in cell death
Cell death induced by CDDP, DQA and the combined
treatment was significantly reduced by pre-incubation
with NAC (10mM) (Fig. 4a & b). Those data showed that
cell death attenuation with the combined therapy in Caco-
2 was more significant than that with the single
treatments, whereas the attenuation in Ishikawa was com-
parable amongst different treatments. Furthermore, cell
Fig. 3 Increases of intracellular ROS level and mitochondrial superoxide in the Caco-2 (a & b) and Ishikawa (c & d) cells upon treatments at 24 h.
The columns represent the fold changes of ROS and mitochondrial superoxide normalised against the untreated controls. Data are mean ± SEM
(N = 3 separate experiments); p values comparing treated and untreated cells were calculated using one-way ANOVA with Tukey multiple
comparison post-hoc analysis; ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. e Comparison of intracellular ROS level
changes upon treatments between the Caco-2 and Ishikawa cells at 24 h. f Comparison of mitochondrial superoxide changes upon treatments
between the Caco-2 and Ishikawa cells at 24 h. Data are mean ± SEM (N = 3 separate experiments); p values comparing the Caco-2 and Ishikawa
cells were calculated using a two-tailed t-test; *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001
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death attenuation upon pre-incubation with NAC was
more significant in Ishikawa compared to Caco-2 (Fig. 4c).
Gene expression levels of anti-oxidants altered upon
treatments
The relative baseline expression levels of the three anti-
oxidant genes, SOD1, SOD2 and CAT, were significantly
lower in the Caco-2 cells compared to the Ishikawa cells
(Fig. 5a-c). Interestingly, all genes were significantly up-
regulated in Caco-2 in the presence of DQA but no sig-
nificant changes were observed with CDDP or the
combined therapy for these three genes (Fig. 5d-f). In
Ishikawa, SOD1 was significantly upregulated in the
presence of CDDP, whereas a significant downregulation
in the combined therapy was observed (Fig. 5g). SOD2
did not show any significant changes upon treatments
(Fig. 5h) while CAT was significantly downregulated in
the presence of all treatments with a further downregu-
lation in the combined therapy (Fig. 5i).
Apoptosis events revoked upon elimination of ROS
To determine whether the observed cell death was due to
ROS-induced apoptosis upon the treatments, apoptosis-
associated proteins were measured in cells with or without
the pre-incubation of NAC. For the cells without NAC
pre-incubation, our western blotting data showed signifi-
cant decreases in the anti-apoptotic protein, BCL-XL,
upon treatments in both cell lines (p < 0.0001; Fig. 6a &
b), whereas the release of cytochrome c was significantly
increased upon the treatments (p < 0.0001; Fig. 6c & d).
Caspase activation assay also showed a significant activa-
tion of caspase-3/7 upon the treatments (Fig. 6e & f). All
above events were significantly attenuated by NAC pre-
incubation.
Fig. 4 Increased cell viability of Caco-2 (a) and Ishikawa (b) upon pre-incubation with NAC (10 mM) prior to drug treatments. The columns
represent the fold changes in cell viability normalised against NAC-free treatment. Data are mean ± SEM (N = 3 separate experiments); p values
comparing NAC-free and NAC-pre-incubated cells were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; ns,
not significant, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. c Comparison of the changes in cell viability between the Caco-2 and
Ishikawa cells upon pre-incubation with NAC. Data are mean ± SEM (N = 3 separate experiments); p values comparing Caco-2 and Ishikawa were
calculated using two-tailed t-test; *p < 0.05 and **p < 0.01
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Discussion
Several previous studies have demonstrated that various
types of cancer cell lines have elevated levels of ROS
compared to normal cell lines [25–27]. Our own ROS
assays conducted with one paired normal-cancer cell
lines to verify this previous observation confirmed it to
be the case (data not shown). Cancer cells also have vari-
ous levels of mtDNAcn which are strictly correlated to
the demand of ATP generated by OXPHOS, “the major
cause of ROS production” [26, 27]. Indeed, our data
showed a positive correlation between the baseline ROS
level and the mtDNAcn amongst 4 human cancer cell
lines of different tissue origins, which confirmed the
previous observation that cells containing larger mtDNA
copy numbers also have higher levels of ROS.
It has been postulated that cisplatin increases the gener-
ation of intracellular ROS which may cause damage to
DNA, proteins and lipids leading to apoptosis [28]. Several
previous studies also related the mechanism of the antitu-
mour effect of dequalinium to an impairment of mito-
chondrial function and the associated ROS generation [2,
14, 19]. Therefore, the potential link between the baseline
ROS levels in cancer cells and their drug sensitivity to-
wards cisplatin and dequalinium was investigated in the
present study. Our results indicated that cancer cells with
high baseline ROS levels were significantly more resistant
Fig. 5 Comparison of the relative expression levels of the SOD1 (a), SOD2 (b) and CAT (c) genes between the untreated Caco-2 and Ishikawa cells.
The columns represent the relative expression levels of the genes using TaqMan qPCR. Data are mean ± SEM (N = 3 separate experiments); p
values comparing the Caco-2 and Ishikawa cells were calculated using two-tailed t-test; *p < 0.05 and **p < 0.01. Gene expression level changes
in the Caco-2 (d-f) and Ishikawa (g-i) cells upon treatments at 24 h. The columns represent the fold changes of the relative expression levels of
the genes normalised against the untreated controls. Data are mean ± SEM (N = 3 separate experiments); p values comparing treated and
untreated cells were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; ns, not significant, *p < 0.05, **p < 0.01,
***p < 0.001 and ****p < 0.0001
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Fig. 6 (See legend on next page.)
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to both cisplatin and dequalinium compared to cells with
low ROS levels. Therefore, baseline ROS levels could be
utilised to predict drug response of cancer cells. As dis-
cussed above, the good correlation between mtDNAcn
and baseline intracellular ROS level in naïve cancer cells
also means that mtDNAcn could be a potential biomarker
to indicate drug sensitivity. Furthermore, our western
blotting and caspase3/7 activity data proved that the mode
of action of the two compounds was indeed through ROS-
induced apoptosis. It is worth mentioning that comparable
mitochondrial content levels were detected in Caco-2 and
Ishikawa using MitoTracker™ Red CMXRos in our study
(data not shown). This finding suggests that baseline ROS
level (either intracellular or MitoSOX) might be more in-
dicative of drug response compared to the population of
the organelles in the cells. Since the Caco-2 cells had the
highest level of mtDNAcn amongst the 4 cancer cell lines,
we speculate that the average copy number of mtDNA per
mitochondrion must be far greater in a single Caco-2 cell
than that in a single Ishikawa cell (it is widely acknowl-
edged that each mitochondrion can contain 2–10 copies
of mtDNA). In addition, our data suggest that MitoSOX
production in the cell may be influenced by the cell’s
mtDNAcn rather than its mitochondrial population.
Currently, cisplatin has limited clinical use due to its se-
vere side effects [29]. Therefore, it is plausible to apply a
lower dose of cisplatin in combination with another anti-
cancer agent in order to reduce the side effects of cisplatin
while enhancing the therapeutic efficacy. In this study, sig-
nificant synergistic effects of CDDP and DQA were ob-
served in both Caco-2 and Ishikawa cells. Those results
were in alignment with previous findings that mitochon-
dria are promising target for anticancer therapy [30].
Furthermore, our data clearly suggest that combining
mitochondria-targeting agents could provide improved ef-
ficacy while reducing side effects of conventional therapy
in treating cancer.
Interestingly, the present study revealed a significant
difference between the Caco-2 and Ishikawa cells in
terms of their response and behaviour to the treatments
at cellular and molecular levels. ROS production upon
drug exposure was significantly elevated in Ishikawa
compared to Caco-2, and the onset of ROS production
was far more rapid in Ishikawa than that in Caco-2. In
addition, the Caco-2 cells responded most significantly
to the combined therapy, whereas similar levels of in-
creased ROS generation were observed in the Ishikawa
cells across all treatments. These results suggested that
CDDP, DQA and their combination could stimulate
more ROS production in cells with relatively low base-
line levels of intracellular ROS. As elevated ROS can
trigger cell death, this explains the significantly higher
sensitivity of the Ishikawa cells towards those treatments
compared to the Caco-2 cells. For cells with relatively
high baseline ROS levels, the combined treatment of
CDDP and DQA could have a greater impact on ROS
production compared to the single treatment of the
compounds. This is in line with our aforementioned
observation that combining CDDP with DQA had a syn-
ergistic effect in killing cancer cells. Since cancer cells
with higher baseline ROS levels could be more resistant
to CDDP, combining CDDP and DQA might warrant a
new strategy to tackle such resistance issues in the
future.
A previous study showed that dequalinium induced a
selective depletion of mitochondrial DNA in carcinoma
cells [18]. Other reports also demonstrated that cisplatin
accumulated in mitochondria formed adducts in mtDNA
that interfered with mtDNA transcription and replica-
tion, and caused ATP deficiency which then led to cell
death [11, 31, 32]. Our results showed significant de-
creases of mtDNAcn in both cancer cell lines upon the
treatments and the relative mtDNAcn value reached the
lowest in samples that had undergone the combined
therapy. Such mtDNA depletion upon treatments would
reduce the expression levels of mtDNA-encoded com-
plex subunits of the electron transport chain (ETC) and
cause more leakage of electrons during OXPHOS, con-
sequently leading to an excessive generation of ROS.
Since mitochondrial membrane depolarisation is an
early key feature of cell death and also could affect res-
piration and increase ROS generation [33], changes in
(See figure on previous page.)
Fig. 6 Western blots showing changes in the protein levels of BCL-XL (a & b) and release of cytochrome c (c & d) in the Caco-2 and Ishikawa
cells upon treatments at 24 h and the effect of NAC pre-incubation in attenuating theses changes in both cell lines. The columns represent the
fold changes of the protein levels normalised against the loading control protein, β-Actin. Data are mean ± SEM (N = 3 separate experiments); p
values comparing CDDP/DQA-treated and -untreated cells without NAC pre-incubation were calculated using one-way ANOVA with Tukey
multiple comparison post-hoc analysis; ***p < 0.001 and ****p < 0.0001. p values comparing NAC-free and NAC-pre-incubated cells undergone the
same CDDP/DQA treatments were calculated using a two-tailed t-test; **p < 0.01, ***p < 0.001 and ****p < 0.0001. Caspase activity assay showing
changes in the caspase-3/7 activity in the Caco-2 (e) and Ishikawa (f) cells upon treatments for 24 h and the effect of NAC pre-incubation in
attenuating theses changes in both cell lines. The columns represent the fold changes of the caspase-3/7 activity normalised against the
untreated cells. Data are mean ± SEM (N = 2 separate experiments); p values comparing CDDP/DQA-treated and -untreated cells without NAC pre-
incubation were calculated using one-way ANOVA with Tukey multiple comparison post-hoc analysis; **p < 0.01 and ***p < 0.001. p values
comparing NAC-free and NAC-pre-incubated cells undergone the same CDDP/DQA treatments were calculated using a two-tailed t-test; *p < 0.05
and **p < 0.01
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the mitochondrial membrane potential upon treatments
were examined in the present study. Indeed, depolarisa-
tions occurred in both cell lines upon treatments in a
time-dependent manner, which indicated that both
CDDP and DQA affected the mitochondrial membrane
potential and interfered with ROS generation. A far
more rapid and overwhelming depolarisation upon DQA
treatment and its combination with CDDP was observed
in both cell lines compared to the MMP changes ob-
served in cells treated with CDDP alone (Additional file 1:
Figure S3). It should be noted that unlike the synergistic
effects on ROS production (Additional file 1: Figure S1)
and cytotoxicity (Additional file 1: Figure S2), the com-
bined treatment did not have a synergistic effect on
mitochondrial depolarisation in both cell lines. In fact,
although the combined treatment had a profound im-
pact on mitochondrial membrane potential, cells treated
with DQA alone showed the most rapid and significant
depolarisation upon the treatment. This could be attrib-
uted to the positive charge of DQA which led to its
prompt and excessive accumulation within the mito-
chondria, consequently neutralising the negative electric
potential on the inner mitochondrial membrane at a
speedy pace. Such swift changes in MMP were observed
in our time course experiments. The impact on MMP
was less severe from the combined treatment compared
to that from DQA alone during the early phase of the
time course particularly at the 1-h and 3-h time points.
This could be due to the fact that only half of the DQA
dosage was administrated to the cells in the combined
treatment, which affected the speed and extent of de-
polarisation in those cells. Data from our recent time
course experiments using another DLC, triphenylpho-
sphine, to replace DQA also showed the same pattern of
MMP reduction in the Caco-2 and Ishikawa cells (data
not shown). Furthermore, the time-dependent changes
in ROS and MMP matched the time course of cell death,
as shown by the relevant time course data. These data
indicate that CDDP and DQA exert cancer cell killing
via mitochondrial dysfunction and ROS-induced cell
death.
As previously reported, CDDP and DQA exert their
antitumour effect through increased ROS generation and
mitochondrial disruption [12, 14, 17]. Therefore, the
present study investigated to what extent the ROS produc-
tion was involved in cell death. When NAC (a powerful
ROS scavenger) was administered to the cells prior to
drug treatment, cell death was significantly reduced, indi-
cating the critical role of enhanced ROS production in
triggering cell death upon various CDDP and DQA treat-
ments. It should be noted that in the Caco-2 cells, death
attenuation with the combined therapy was more signifi-
cant than that with the single treatment, which was in
alignment with the highest ROS production level upon
the combined treatment as compared to single treatment.
Similarly, the attenuation effects in the Ishikawa cells were
comparable among different treatments, indicating an
equal (or non-treatment-specific) production level of ROS
following the treatments, which was indeed the case as
supported by the ROS data of the Ishikawa cells. Further-
more, the cell death attenuation by NAC was more effect-
ive for Ishikawa compared to Caco-2, indicating that ROS
had a more important role in mediating cell death in Ishi-
kawa. Those results collectively confirmed that baseline
ROS levels could influence how cancer cells respond to
the same treatment, as demonstrated by the Caco-2 and
Ishikawa cells in this study. Moreover, our data highlight
the fact that cancer cells with lower baseline levels of
intracellular ROS would respond better to ROS-
stimulating therapy by generating more ROS compared to
cells with higher baseline levels of ROS. Hence, the exces-
sive ROS induced by the treatment could be the main
cause of cell death in cells with low baseline ROS, whereas
different mechanisms might play a role in parallel with
ROS in causing cell death in cells with high baseline ROS.
To gain further insight into the reason behind the dif-
ferences in the baseline ROS level between the Caco-2
and Ishikawa cells, and the mechanisms underlying
treatment-induced ROS production, the expression
levels of three antioxidant genes, SOD1, SOD2 and CAT,
were analysed. Our data showed that the expression
levels of these antioxidant genes were significantly lower
in the naïve Caco-2 cells compared to Ishikawa. This
could explain the differences in the baseline ROS level
between the two cell lines, since cells producing less an-
tioxidants are expected to have an inefficient ROS scav-
enging system, resulting in higher baseline ROS levels in
those cells. Interestingly, all three genes were signifi-
cantly upregulated only in the Caco-2 cells treated with
DQA. Those results indicated that DQA treatment pro-
voked an antioxidant response in the Caco-2 cells which
remained silent upon exposure to CDDP. It is possible
that in the Caco-2 cells, CDDP might have a direct im-
pact on the expression levels of other antioxidants such
as glutathione (GSH) and glutathione related enzymes
(e.g. glutathione S-transferase/GST and glutathione per-
oxidase/GPX) which were not analysed in the present
study. Potentially, CDDP exposure might also influence
the expression and/or activity levels of certain transcrip-
tion factors such as nuclear factor erythroid 2-related
factor 2 (Nrf2) which regulates the expression of genes
involved in the cellular antioxidant system and activating
protein-1 (AP-1) which responds to cellular stresses in-
cluding oxidative stress (reviewed in Ref.s [34–36]). As
to the Ishikawa cells, the expression profiles of these
antioxidant genes were less consistent compared to
those of Caco-2. However, both SOD1 and CAT were
significantly downregulated in Ishikawa upon the
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combined treatment. The above results suggest that can-
cer cells with high baseline ROS levels might have rela-
tively low expressions of antioxidant genes. However,
upon ROS-stimulating treatment, those cells could up-
regulate their antioxidants significantly as a protective
mechanism, rendering them more resistant to the treat-
ment. On the other hand, cells with low baseline ROS
levels might have saturated their antioxidant system and,
therefore, could not defend themselves efficiently against
ROS-stimulating compounds, as demonstrated by the
significantly higher sensitivity levels of Ishikawa com-
pared to those of Caco-2 in this study.
It should be emphasised that another advantage of
using mitochondria-targeting cations in anticancer ther-
apy, apart from the synergistic killing effect, is that those
compounds preferentially enter mitochondria in cancer
cells which generally have higher membrane potentials
compared to those of mitochondria in normal cells. This
allows cations to selectively target cancer cells and accu-
mulate more rapidly in their mitochondria [15]. Our
data comparing the prostate cancer (PC-3) and normal
(PNT-2) cell lines confirmed the preferential targeting of
cancer cells by DQA. Due to time and funding limita-
tions, we were unable to carry out further in vivo work
in the present study. However, we fully recognise that it
is critical to test this in vitro phenomenon in vivo in
order to properly evaluate the potential of DLCs in clin-
ical practice. If proven, DLCs could offer cancer-specific
therapy with significantly reduced side effects. MKT-077
was the first DLC to be tested in clinical trials which
were terminated due to renal toxicity [15, 17]. Therefore,
more suitable DLCs still need to be trialed.
Conclusions
This study confirms that cisplatin and dequalinium ex-
hibit different cytotoxic efficacy according to the base-
line ROS levels within the cancer cells. To our
knowledge, this is the first study showing that baseline
ROS levels of cancer cells might be utilised to predict
drug response. As measuring ROS in tissues is technic-
ally challenging, our data suggest that mtDNAcn could
be a more efficient biomarker to indicate the response to
mitochondria-targeting therapy. Our findings also sug-
gest that combining conventional chemotherapy with
mitochondria-targeting therapy enhances cell death and
allows reduced doses of the conventional drug. As the
above conclusions have been drawn based on limited
in vitro work, further studies engaging a wider range of
cell lines as well as in vivo experiments will be required
to confirm the present findings. Nevertheless, this study
has provided an insight into understanding the influence
of intracellular ROS on drug sensitivity, and may lead to
the development of new therapeutic strategies to im-
prove anticancer drug efficacy.
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